Haleon has confirmed plans to invest £130m in a Global Oral Health Innovation Centre in Weybridge, Surrey.
The 90,000 sq. ft building is expected to open in 2027 and will be home to 450 staff. It will incorporate state-of-the-art and digitally enabled research laboratories alongside traditional workspaces and a dedicated consumer behavioural research facility. The company stated that the facilities will “drive innovation across Haleon’s Oral Health portfolio”, which includes Sensodyne, Polident/Poligrip, Aquafresh and Corsodyl.
The investment was referenced by the UK Government as part of its International Investment Summit this week.
Brian McNamara, CEO of Haleon, commented: “Our decision to locate our Global Oral Health Innovation Centre in Weybridge reflects our confidence in the UK as a great place for a global company like ours to thrive. This facility is central to our efforts to attract and retain the best talent to fuel our growth and the continuous innovation which is so vital for delivering better everyday health. We support the UK Government’s ambition to drive future investment in the UK to cement its status as a leading centre for life sciences, R&D and innovation.”
